Previous studies had analyzed smaller patient cohorts (14–45 cases) and found highly variable results including lower [9], [10] and higher [7], [8] numbers of “SSTR2-positive” prostate cancers as compared to our data. Here, SSTR2 is linked to prostate carcinoma.